BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 19411101)

  • 1. The importance of VTE prevention after orthopaedic surgery.
    Becker RC
    Lancet; 2009 May; 373(9676):1661-2. PubMed ID: 19411101
    [No Abstract]   [Full Text] [Related]  

  • 2. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
    Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
    Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New agents for orthopaedic thromboprophylaxis: caution essential, but time will tell.
    Verma AK
    ANZ J Surg; 2009 Nov; 79(11):773-4. PubMed ID: 20078521
    [No Abstract]   [Full Text] [Related]  

  • 4. Venous thromboembolism after total hip arthroplasty and total knee arthroplasty: current and future perspectives. Epilogue.
    Merli G
    Am J Manag Care; 2011 Feb; 17(1 Suppl):S33. PubMed ID: 21548181
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty.
    Kwong LM
    Am J Manag Care; 2011 Feb; 17(1 Suppl):S22-6. PubMed ID: 21517652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials.
    Friedman RJ
    Orthopedics; 2011 Oct; 34(10):795-804. PubMed ID: 21956181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.
    Lereun C; Wells P; Diamantopoulos A; Rasul F; Lees M; Sengupta N
    J Med Econ; 2011; 14(2):238-44. PubMed ID: 21385145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.
    Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
    J Med Econ; 2011; 14(6):824-34. PubMed ID: 22023098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban for thromboprophylaxis.
    Schuman EP
    N Engl J Med; 2008 Nov; 359(20):2174; author reply 2175-6. PubMed ID: 19005203
    [No Abstract]   [Full Text] [Related]  

  • 10. Rivaroxaban for thromboprophylaxis.
    Lotke PA
    N Engl J Med; 2008 Nov; 359(20):2174; author reply 2175-6. PubMed ID: 19009675
    [No Abstract]   [Full Text] [Related]  

  • 11. Rivaroxaban: an oral factor Xa inhibitor.
    Thomas TF; Ganetsky V; Spinler SA
    Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticoagulation with {blacktriangledown}dabigatran or{blacktriangledown}rivaroxaban.
    Drug Ther Bull; 2009 Oct; 47(10):116-20. PubMed ID: 19809086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.
    Monreal M; Folkerts K; Diamantopoulos A; Imberti D; Brosa M
    Thromb Haemost; 2013 Nov; 110(5):987-94. PubMed ID: 23965805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivaroxaban for thromboprophylaxis.
    ten Cate H; Hamulyak K
    N Engl J Med; 2008 Nov; 359(20):2174-5; author reply 2176. PubMed ID: 19009676
    [No Abstract]   [Full Text] [Related]  

  • 15. Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.
    Duggan ST
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):57-72. PubMed ID: 22272729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
    Nieto JA; Espada NG; Merino RG; González TC
    Thromb Res; 2012 Aug; 130(2):183-91. PubMed ID: 22425218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective factor Xa inhibition for thromboprophylaxis.
    Eikelboom JW; Weitz JI
    Lancet; 2008 Jul; 372(9632):6-8. PubMed ID: 18582929
    [No Abstract]   [Full Text] [Related]  

  • 18. Upcoming oral factor Xa inhibitors for venous thromboembolism prophylaxis in patients undergoing major orthopedic surgery: rivaroxaban (Xarelto) and apixaban (Eliquis) review.
    Lee S; White CM
    Conn Med; 2012 Jan; 76(1):39-42. PubMed ID: 22372178
    [No Abstract]   [Full Text] [Related]  

  • 19. Therapeutic index of anticoagulants for prevention of venous thromboembolism following orthopedic surgery: a dose-response meta-analysis.
    Mandema JW; Boyd RA; DiCarlo LA
    Clin Pharmacol Ther; 2011 Dec; 90(6):820-7. PubMed ID: 22048231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New anticoagulants--the path from discovery to clinical practice.
    Lohrmann J; Becker RC
    N Engl J Med; 2008 Jun; 358(26):2827-9. PubMed ID: 18579818
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.